



**ASX & MEDIA RELEASE
2 APRIL, 2012**

INTERIM DIVIDEND PAYMENT – 16 APRIL 2012

On 16 April, 2012, Novogen Limited (ASX: NRT NASDAQ: NVGND) will be paying an interim dividend. The dividend comprises 90% of the Units received by Novogen from its majority owned subsidiary Marshall Edwards, Inc., through its Rights Offering.

The Marshall Edwards Rights Offering was previously announced to the market by Novogen by its announcement dated 22 January, 2012.

The dividend will be paid to all Novogen shareholders who are recorded on the register at 5.00pm on the record date of 13 April, 2012, and full details of the Units offered under the Marshall Edwards Rights Offering will be mailed to shareholders on 17 April, 2012.

About Novogen Limited

Novogen Limited (ASX: NRT Nasdaq: NVGN) is an Australian biotechnology company based in Sydney, Australia. Novogen conducts research and development on oncology therapeutics through its subsidiary, Marshall Edwards, Inc., and is developing glucan technology through its subsidiary, Glycotex, Inc. More information on the Novogen group of companies can be found at www.novogen.com.

ISSUED FOR	:	NOVOGEN LIMITED
LISTINGS	:	ASX (CODE NRT), NASDAQ (CODE NVGND).
FOR FURTHER	:	WILLIAM D RUECKERT, CHAIRMAN, NOVOGEN LIMITED TEL +612 9878 0088 http://www.marshalledwardsinc.com
ISSUED BY	:	WESTBROOK COMMUNICATIONS
CONTACT	:	IAN WESTBROOK TEL (02) 9231 0922